China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

A research team led by the University of Oxford's Department of Engineering Science has shown it is possible to engineer a ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

Carvykti sales surge, MRD FDA guidance speeds label expansion, and strong cash runway. Click for more on LEGN stock.

So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs — the most ever for the ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

The discussion focuses on how KAIMRC integrates clinical research, biobanking, data infrastructure, and translational science ...

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share. But ...

At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best set yourself up for success, adapt your approach to the specific scientific ...

Stay updated on biotech layoffs in 2026! Each week, we track and analyze industry layoffs, their causes, and their impact.

Shares of biotech companies were outpacing the broader market on Thursday. The State Street SPDR S&P Biotech ETF was up 2.7%, compared with the 0.8% gain of the S&P 500. A significant portion of these ...